CYNATA THERAPEUTICS LIMITED
ASX:CYPPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 96.8% of what they think they own, once every option and right converts.
Runway under 2 quarters; share count grew 35% in 24 months; 5 cash raises in 24 months
CYNATA THERAPEUTICS LIMITED's ordinary share count increased 34.7% between September 2024 and May 2026, its latest share-count filing, to 243M shares. The company raised capital five times in the past 24 months for total disclosed proceeds of A$11.7M, most recently an A$913K Renounceable Entitlement Offer in October 2026. Options and rights could convert into 8M new shares, representing 3.3% of the current share count, none of which are in the money; the nearest expiry is November 2027. The company reports under 2 quarters of funding at the recent spend rate. Three proposed securities issues (Appendix 3B) are pending, with the nearest expected issue date in October 2026.
Quick answers · 5
Is CYP raising capital?
Cynata Therapeutics has 3 proposed issues of securities pending under Appendix 3B as at 28 Oct 2026; the most recent raise announced is Renounceable Entitlement Offer of $913k on 8 Oct 2026.
How much placement capacity does CYP have left?
About 28% of the 15% placement capacity left, about 72% used in 12 months (estimate). Under ASX Listing Rule 7.1 a company may place up to 15% of its shares in 12 months without shareholder approval.
How much cash does CYP have?
In its quarterly cash report for the quarter ended 30 Sept 2026, Cynata Therapeutics reported $175k of cash and estimated 0.1 quarters of funding available at its current rate of spending. That is the company's own estimate.
When do CYP's options expire?
Unexercised options and rights equal 3.3% of Cynata Therapeutics's shares on issue; the nearest expiry is Nov 2027.
How much has CYP's share count grown?
Cynata Therapeutics has 243.5M shares on issue as at 28 Oct 2026, up 34.7% over 24 months according to its Appendix 2A filings.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 11 Sept 2026 | 3H · cancellation | CYP : ORDINARY FULLY PAID | 243.5M | Appendix 3H |
| 10 July 2026 | 3H · cancellation | CYP : ORDINARY FULLY PAID | 243.5M | Appendix 3H |
| 8 May 2026 | 2A · quoted issue | CYP : ORDINARY FULLY PAID | 243.5M | Appendix 2A |
| 7 Apr 2026 | 3H · cancellation | CYP : ORDINARY FULLY PAID | 237.5M | Appendix 3H |
| 1 Dec 2025 | 3H · cancellation | CYP : ORDINARY FULLY PAID | 237.5M | Appendix 3H |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
5 cash raises in the last 24 months · 3 in the last 12 months
Retail offer
An offer existing holders can take part in — the one structural advantage retail has in a raise. Dated recently and not yet recorded as complete.
Closing dates are not in the filings this site holds. Check the company's own announcement below before acting on this.
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
At $0.012 today, 0 securities are in the money (0.0% of shares on issue). No price up to ten times today’s switches on any more priced supply.
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 8.0M more carries an exercise price above ten times today’s — off the right of this axis, and in every total on this page.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| CYPAR | Options | Price-triggered | $0.51 | 23 Nov 2027 | 300k | Filing |
| CYPAS | Options | Price-triggered | $0.18 | 30 June 2028 | 2.0M | Filing |
| CYPAU | Options | Price-triggered | $0.28 | 12 Sept 2028 | 1.0M | Filing |
| CYPAE | Options | Price-triggered | $0.18 | 20 Nov 2028 | 1.9M | Filing |
| CYPAF | Options | Price-triggered | $0.20 | 16 Jan 2029 | 975k | Filing |
| CYPAT | Options | Price-triggered | $0.29 | 17 Apr 2029 | 1.8M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 29 Nov 2025 | Dr Darryl Maher | Sell | 117k | 220k | — | — | 3Y notice |
| 29 Nov 2025 | Dr Geoffrey Brooke | Sell | 313k | 2.5M | — | — | 3Y notice |
| 29 Nov 2025 | Dr Paul K Wotton | Sell | — | 300k | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.